Objectives: Acute ischemic strokes (stroke) are frequent and severe extracardiac complications in infective endocarditis (IE). Since intravenous thrombolysis (IV-thrombolysis) is contraindicated, mechanical thrombectomy (thrombectomy) offers potential benefit. We aimed to compare thrombectomy efficacy and safety between IE-related and general stroke cases.
Methods: Multicenter study of consecutive IE cases treated with thrombectomy at nine stroke centers in Spain from 2011 to 2022. Using propensity score matching, 50 IE cases were 1:4 matched with non-IE stroke patients (n=200). Efficacy was defined by successful recanalization rates [modified treatment in cerebral ischemia scale (mTICI) ≥2b], neurological improvement at 24 hours [decrease of National Institutes of Health Stroke Scale (NIHSS) compared to baseline], and good neurological outcome rates at 3 months [modified Rankin scale (mRS) ≤ 2]. Safety was assessed by intracranial hemorrhage (IC-hemorrhage), symptomatic IC-hemorrhage, crude mortality, and stroke-related mortality.
Results: Among 54 IE cases, 50 were matched with 200 controls. Successful recanalization was similarly achieved in both groups (76% vs 83%). Median NIHSS at 24h was comparable, with analogous rates of neurological improvement (78% vs 78%), and early dramatic response (48% vs 46.5%). No differences were seen regarding IC-hemorrhage rates, except for when prior IV-thrombolysis was given. Although crude mortality was higher in the IE cohort, no differences were seen in stroke-related mortality (12% vs 15%). At three months, mRS scores of the two groups were superimposable.
Conclusions: Thrombectomy in IE is as effective and safe as in non-IE patients, and prior IV-thrombolysis could decrease the procedural safety. Clinical practice guidelines may consider including the recommendation to perform thrombectomy alone in IE-related stroke.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cmi.2025.02.008 | DOI Listing |
J Dtsch Dermatol Ges
March 2025
Department of Plastic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Acne scarring significantly affects physical appearance and psychological well-being, prompting the exploration of various treatment options, including ablative and non-ablative laser therapies. The debate around their efficacy and safety persists, underscoring the need for a comprehensive analysis. This meta-analysis compares the therapeutic outcomes and safety profiles of ablative and non-ablative laser treatments for acne scars, based on a comprehensive review of clinical trials conducted up to March 2023.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient's T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME).
View Article and Find Full Text PDFFront Immunol
March 2025
Rheumatology Unit, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population. Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6 receptor, has emerged as an effective treatment for RA. This narrative review provides an update on TCZ's efficacy and safety based on data from randomized controlled trials (RCTs) and real-world evidence (RWE).
View Article and Find Full Text PDFFront Pharmacol
February 2025
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Introduction: Modern medical treatment of insomnia is often associated with issues like addiction, drug resistance, and a high risk of relapse post drug withdrawal. To tackle these challenges, the Chinese medicine formula Shuhe granule (SHG) has been employed in insomnia treatment at Guangdong Provincial Hospital of Chinese Medicine. Despite this, there is currently a lack of reliable evidence from evidence-based trials to support the widespread use of SHG in insomnia treatment.
View Article and Find Full Text PDFFront Pharmacol
February 2025
Organon, Jersey City, NJ, United States.
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars. Hence, this aims to explore the role of real-world evidence on biosimilars by showcasing how real-world evidence studies have contributed to addressing key questions affecting biosimilar market access. We find that the comparable efficacy and safety of a biosimilar and the reference product is corroborated by real-world evidence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!